Rong-juan Pei
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).
Journal: EClinicalMedicine
Published: September 08, 2023
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
Journal: Vaccine
Published: July 06, 2023
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.
Journal: Emerging microbes & infections
Published: June 10, 2022
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
Journal: Chinese medical journal
Published: July 26, 2021
Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Journal: Acta pharmacologica Sinica
Published: August 07, 2020
Histone deacetylase 3 promotes innate antiviral immunity through deacetylation of TBK1.
Journal: Protein & cell
Published: April 12, 2020
Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways.
Journal: World journal of gastroenterology
Published: November 06, 2013
The protamine-like DNA-binding protein P6.9 epigenetically up-regulates Autographa californica multiple nucleopolyhedrovirus gene transcription in the late infection phase.
Journal: Virologica Sinica
Published: October 28, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026